Background
==========

Cirrhosis results from chronic liver disease and is associated with the development of hepatocellular carcinoma and even death. The prognosis of chronic liver disease depends on the severity of hepatic fibrosis, which is the accumulation of extracellular matrix proteins. Because later stages of hepatic fibrosis are irreversible and lead to liver failure and death, preventing the progression of hepatic fibrosis to cirrhosis is important. Chronic liver disease management is an important issue in daily practice, and it depends on the degree of liver cirrhosis. Liver biopsy remains the criterion standard for assessment of hepatic fibrosis \[[@b1-medscimonit-25-7169]\]. However, this method is expensive, needs expertise, and has the potential for procedural complications, including pain, bleeding, perforation, and even death \[[@b2-medscimonit-25-7169]\]. Sampling error and interpretational variability are also potential limitations \[[@b3-medscimonit-25-7169],[@b4-medscimonit-25-7169]\]. Thus, non-invasive methods are needed for the evaluation of hepatic fibrosis \[[@b5-medscimonit-25-7169]\].

Acoustic radiation force impulse (ARFI) has been proposed in recent studies as a reliable and accurate non-invasive technique for assessing hepatic fibrosis \[[@b6-medscimonit-25-7169]\]. ARFI performed better than a scoring system based on visual assessment of conventional ultrasound images by experienced radiologists in correlation with Child-Pugh scores and liver function tests and better than aspartate-to-platelet ratio in predicting severe fibrosis and cirrhosis among alcoholic liver disease patients \[[@b7-medscimonit-25-7169]\].

Recently, a glycan-based immunoassay has been introduced as a convenient non-invasive method of evaluating hepatic fibrosis; it targets WFA^+^-M2BP as a serum biomarker \[[@b8-medscimonit-25-7169]\]. The feasibility of WFA^+^-M2BP for assessing hepatic fibrosis was evaluated and some studies recommended it as an accurate method for staging hepatic fibrosis \[[@b9-medscimonit-25-7169]\].

The present study aimed to assess and compare the diagnostic accuracy of WFA^+^-M2BP and ARFI for estimating the stage of hepatic fibrosis among chronic liver disease patients.

Material and Methods
====================

This was a retrospective cross-sectional study. Institutional Review Board approval was obtained (approval dated 20 May 2016). Between April 2016 and April 2017, 108 patients with hepatic tumors underwent hepatectomy in our institute (Changhua Christian Hospital). The inclusion criteria of our study were: (1) patients had underlying chronic liver disease, and (2) the time interval between measurement (ARFI and serum WFA^+^-M2BP levels) and hepatectomy was less than 1 week. We enrolled 70 patients. Patient characteristics, age, sex, body mass index (BMI), underlying liver disease, and laboratory data were recorded ([Table 1](#t1-medscimonit-25-7169){ref-type="table"}).

ARFI Elastography
-----------------

ARFI was performed by experienced hepatologists who were blinded to the clinical information. A virtual touch tissue quantification (VTTQ) system (ACUSON S2000, Siemens AG) that uses an acoustic push pulse to generate shear waves was utilized while the patient was fasting and in supine position. The patients were asked to hold their breath. Then, the ARFI measurement was taken while patients held their breath to minimize breathing motion. The right lobe of the liver was accessed under conventional ultrasound guidance. An area of the liver free of major veins and portal tracts and having no focal pathology was selected so that the shear wave speed could be calculated. This absolute numerical value is related to the tissue stiffness within the region of interest (ROI) (1.0×0.5 cm). The results were presented in meters per second (m/s) \[[@b10-medscimonit-25-7169],[@b11-medscimonit-25-7169]\]. The measurement of ARFI in the right lobe of the liver was performed by placing the ultrasonic probe on right intercostal spaces with light pressure, and an ROI was placed at a depth 2 cm below the liver capsule. Reliable velocity values were defined as the median of 10 valid measurements with a success rate greater or equal to 60% and an interquartile range less than 30% of the median value for the measurements \[[@b12-medscimonit-25-7169]\].

WFA^+^-M2BP measurement
-----------------------

Serum samples were collected at the time of ARFI measurement. Serum WFA^+^-M2BP was quantified by lectin-Ab sandwich immunoassay using a fully automated immunoanalyzer (HISCL-800 Sysmex Co., Kobe, Japan) \[[@b13-medscimonit-25-7169]\]. These values were successfully adjusted after every reaction during the automatic assay, and the maximum testing time was 17 min. The measured values of WFA^+^-M2BP conjugated to WFA were indexed with the obtained values using the following equation \[[@b8-medscimonit-25-7169],[@b13-medscimonit-25-7169]\]:
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Histologic evaluation
---------------------

The results of histopathological analysis of hepatectomy specimens was used to confirm a diagnosis of hepatic fibrosis. Formalin-fixed, paraffin-embedded (FFPE) tissue samples were sectioned and stained with hematoxylin and eosin (HE) and Masson trichrome. All specimens were reviewed by an experienced hepatic pathologist blinded to clinical data. Hepatic fibrosis was stratified to stages 0--4 based on the METAVIR scoring system. Stages F0, F1, F2, F3, and F4 were defined as absent, portal fibrosis, portal fibrosis with few septa, and cirrhosis, respectively.

Statistical analysis
--------------------

All continuous data are presented as mean ± standard deviation (SD). A receiver operating characteristic (ROC) curve analysis and the highest Youden index were applied to assess the optimal cutoff value for WFA^+^-M2BP and ARFI median (VTTQ). The area under the ROC curve (AUC) was used to measure the diagnostic accuracy in each degree of hepatic fibrosis and with different hepatitis virus infection status. The difference between 2 AUCs were compared by DeLong's test. A P value of less than 0.05 was considered to indicate statistical significance. All statistical analyses were performed using MedCalc for Windows, version 16.8.4 (MedCalc Software bvba, Ostend, Belgium).

Results
=======

Using ROC analysis, the diagnostic performance of ARFI examination in characterization of hepatic fibrosis stage is shown in [Table 2](#t2-medscimonit-25-7169){ref-type="table"}. The AUC for differentiating F0--F2 from F3--F4 with ARFI examination was 0.79 (*p*\<0.05) in the total group, 0.81 in the hepatitis B virus (HBV) subgroup, and 0.69 in the hepatitis C virus (HCV) subgroup. The diagnostic performance of WFA^+^-M2BP examination in characterization of hepatic fibrosis stage with ROC analysis is shown in [Table 3](#t3-medscimonit-25-7169){ref-type="table"}. The AUC for differentiating F0--F2 from F3--F4 with the WFA^+^-M2BP examination was 0.71 in the total group, 0.65 in the HBV subgroup, and 0.84 in the HCV subgroup. In the HBV subgroup, WFA^+^-M2BP values showed no significant difference between F0--2 and F3--4 fibrosis stages. The diagnostic performance of the WFA^+^-M2BP examination for the HBV subgroup was inferior to that of the HCV subgroup.

ROC analysis was used to compare the diagnostic performance of ARFI examination *vs.* WFA^+^-M2BP values in differentiating fibrosis stages F0--F2 from F3--F4, showing no significant differences for the total group, the HBV subgroup, or HVC subgroup ([Table 4](#t4-medscimonit-25-7169){ref-type="table"}). In the HBV subgroup, ARFI examination had a larger AUC than WFA^+^-M2BP in detecting severe fibrosis (≥F3), but the difference was not significant. In contrast, serum WFA^+^-M2BP examination showed a better AUC in detecting significant fibrosis (≥F3) among the HCV subgroup, but there was no significant difference between the 2 examinations.

Discussions
===========

Our results revealed no significant diagnostic difference between serum WFA^+^-M2BP values (AUC, 0.71) and ARFI examination (AUC, 0.79) (p=0.206) in characterizing patients with severe fibrosis (F≥3). Kuno et al. \[[@b13-medscimonit-25-7169]\] developed a rapid method using a glycan-based immunoassay, targeting WFA^+^-M2BP as a non-invasive biomarker for hepatic fibrosis. WFA^+^-M2BP now plays an important role in the evaluation of hepatic fibrosis. Toshima et al. \[[@b9-medscimonit-25-7169]\] reported an AUC of 0.812 for the diagnosis of fibrosis (F≥3) using serum WFA^+^-M2BP values, similar to the AUC of 0.814 obtained using ARFI examination. Our results also demonstrated no significant differences in the characterization of patients with severe fibrosis (F≥3) in the HBV (*p*=0.082) and HCV (*p*=0.178) subgroups. According to our results, WFA^+^-M2BP could serve as a non-invasive biomarker of hepatic fibrosis, and its diagnostic performance was similar to that of ARFI elastography.

Toshima et al. \[[@b9-medscimonit-25-7169]\]reported that WFA^+^-M2BP serum levels accurately reflect the degree of hepatic fibrosis, with an AUC of 0.81 in determining an advanced histologic stage (F≥3). In our study, the AUC of WFA^+^-M2BP serum levels in fibrosis stage ≥3 was only 0.71. This difference may be due to 2 reasons. In the Toshima et al. study, the number of patients with a fibrosis score of F3 was relatively small (16 patients, 8%). Another reason is that only 10% of their patients had HBV, but in our study, 47.1% of patients had HBV and 40% of patients had HCV. The AUC for the HCV subgroup was 0.836 in our study, similar to that of Toshima's study. The AUC for the HBV subgroup was only 0.65. Our results suggest that the diagnostic performance of serum WFA^+^-M2BP is more accurate in HCV patients than in HBV patients.

In our study, the ARFI elastography showed 86.11% sensitivity and 70.6% specificity in the diagnosis of patients with F≥3. This result is similar to that of Bota et al. \[[@b14-medscimonit-25-7169]\], but the diagnostic performance of ARFI elastography was better in the HBV subgroup than in the HCV subgroup. This differs from the study by Sporea et al. \[[@b15-medscimonit-25-7169]\], which found that the correlation of liver stiffness measurements assessed by ARFI elastography with histological hepatic fibrosis was similar in patients with chronic hepatitis C *vs.* those with chronic hepatitis B. The difference might due to small case numbers in each fibrosis stage of the 2 subgroups. The diagnostic discrepancy between HBV and HCV patients needs further elucidation.

With ROC analysis in characterization of patients with severe fibrosis (≥F3), the AUC for serum WFA^+^-M2BP examination was 0.84 with a cutoff value of 2.21 for the HCV subgroup, and the AUC was 0.65 with a cutoff value of 0.96 for the HBV subgroup. Nishikawa et al. \[[@b16-medscimonit-25-7169]\] reported the same phenomenon (COI: 3.79 for the HCV subgroup and COI: 1.79 for the HBV subgroup). The difference between the HBV and HCV subgroups may be because the pathogenic mechanisms in chronic hepatitis B infections are quite different from those in chronic hepatitis C infections. The liver histologies in the chronic hepatitis B and hepatitis C groups were also very different. Hepatitis B-related cirrhosis showed large regenerative nodules with thin fibrous septa, whereas hepatitis C-related cirrhosis showed small regenerative nodules with thick fibrous septa \[[@b17-medscimonit-25-7169],[@b18-medscimonit-25-7169]\]. These differences may lead to different mechanisms underlying hepatic fibrosis, resulting in different cutoff values and diagnostic performances for the HCV and HBV subgroups. Further studies are needed to clarify the individual cutoff values for each etiology of chronic liver disease.

Measuring the serum WFA^+^-M2BP value is a rapid and non-invasive method for assessing significant hepatic fibrosis. According to our results, its diagnostic performance is as good as that of ARFI elastography. This study is simple and easily reproducible. Therefore, it might also be considered for follow-up studies during antiviral therapy of chronic liver disease. AALD guidelines recommend immediate treatment for patients with advanced liver disease (≥F3) \[[@b19-medscimonit-25-7169]\]. In Taiwan, because public resources limit the ability to treat all HCV-infected patients, the patients with advanced hepatic fibrosis are regularly treated first. As a reliable non-invasive method with no need for imaging, the serum WFA^+^-M2BP examination might be suitable for disease characterization and therapeutic response follow-up in patients with chronic liver disease.

Our study has some limitations. First, our study design was retrospective with a small number of patients. A prospective study with a large number of cases might be needed. Second, all patients in our study underwent hepatectomy due to liver tumors. The hepatic fibrosis stages were determined according to the normal liver tissue around the tumors of surgical specimens, but there may be differences from peritumoral normal parenchyma, and the whole hepatic fibrosis condition might need to be considered. However, when the sample size is very small, surgical specimens are more accurate and reliable than liver biopsies.

Conclusions
===========

The diagnostic accuracy of serum WFA^+^-M2BP value is comparable to that of ARFI elastography in characterization of severe hepatic fibrosis. As its measurement is rapid, simple, and non-invasive, serum WFA^+^-M2BP value might be useful in initial screening and therapeutic follow-up for patients with chronic liver disease.
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###### 

Clinical characteristics of the 70 patients enrolled in our study.

  --------------------------------------------------------------
                                     Total number of patients\
                                     N=70 (%)
  -------------------- ------------- ---------------------------
  Age (years)                        64.51±10.71

  Gender               Male          58 (82.9)

  Female               12 (17.1)     

  BMI (kg/m^2^)                      24.47±3.47

  Underlying disease   HBV           33 (47.1)

                       HCV           28 (40.0)

                       HBV+HCV       1 (1.4)

                       Alcoholic     3 (4.3)

                       Cryptogenic   5 (7.1)

  METAVIR Score        0             4 (5.7)

                       1             13 (18.6)

                       2             17 (24.3)

                       3             11 (15.7)

                       4             25 (35.7)

  Fatty liver          0             43 (61.4)

                       1             24 (34.3)

                       2             3 (4.3)

  AST(U/L)                           76.24±87.90

  ALT(U/L)                           64.11±56.68

  Bilirubin                          0.93±0.45

  PLT                                183.97±79.29

  APTT                               34.47±3.33

  PT                                 11.42±1.09

  INR                                1.08±0.10

  Activity             0             19 (27.1)

                       1             51 (72.9)

  M2BPGi (C.O.I.)                    2.13±2.04

  ARFI median                        2.06±0.66
  --------------------------------------------------------------

SD -- standard deviation; HBV -- hepatitis B virus; HCV -- hepatitis C virus; AST -- aspartate aminotransferase; ALT -- alanine aminotransferase. Values are depicted as mean ±SD.

###### 

ARFI performance in estimation of liver fibrosis stage.

                        AUC     95% CI         Sensitivity   Specificity   P value
  --------------------- ------- -------------- ------------- ------------- ----------
  **Total; N=70**                                                          
  F0--F1 *vs.* F2--F4   0.760   0.643--0.854   73.58         76.47         0.0005
  F0--F2 *vs.* F3--F4   0.791   0.677--0.879   86.11         70.59         \<0.0001
  F0--F3 *vs.* F4       0.827   0.718--0.907   96.00         62.22         \<0.0001
  **HBV; n=33**                                                            
  F0--F1 *vs.* F2--F4   0.747   0.566--0.881   85.19         66.67         0.0919
  F0--F2 *vs.* F3--F4   0.816   0.643--0.929   87.50         76.47         0.0001
  F0--F3 *vs.* F4       0.813   0.640--0.927   92.31         70.00         0.0001
  **HCV; n=27**                                                            
  F0--F1 *vs.* F2--F4   0.800   0.607--0.926   95.65         60.00         0.0130
  F0--F2 *vs.* F3--F4   0.694   0.493--0.853   77.78         60.00         0.0697
  F0--F3 *vs.* F4       0.856   0.671--0.959   90.91         70.59         \<0.0001

AUC -- area under the ROC (receiver operating characteristic) curve; CI -- confidence interval. The AUC was used to measure diagnostic accuracy in each degree of hepatic fibrosis and different hepatitis virus infection status.

###### 

Serum WFA^+^-M2BP performance in estimation of liver fibrosis stage.

                        AUC     95% CI         Sensitivity   Specificity   P value
  --------------------- ------- -------------- ------------- ------------- ----------
  **Total; N=70**                                                          
  F0--F1 *vs.* F2--F4   0.600   0.476--0.716   73.58         52.94         0.1995
  F0--F2 *vs.* F3--F4   0.712   0.591--0.814   72.2          61.76         0.0006
  F0--F3 *vs.* F4       0.721   0.601--0.822   84.00         55.56         0.0004
  **HBV; n=33**                                                            
  F0--F1 *vs.* F2--F4   0.580   0.369--0.749   85.19         50.0          0.5706
  F0--F2 *vs.* F3--F4   0.651   0.466--0.808   81.25         58.82         0.1404
  F0--F3 *vs.* F4       0.692   0.508--0.840   84.62         65.00         0.0535
  **HCV; n=27**                                                            
  F0--F1 *vs.* F2--F4   0.822   0.631--0.940   56.52         100.00        0.0006
  F0--F2 *vs.* F3--F4   0.836   0.648--0.948   72.22         100.00        \<0.0001
  F0--F3 *vs.* F4       0.791   0.597--0.921   72.73         76.47         0.0012

AUC -- area under the ROC (receiver operating characteristic) curve; CI -- confidence interval. The AUC was used to measure diagnostic accuracy in each degree of hepatic fibrosis and different hepatitis virus infection status.

###### 

Comparison of ARFI and WFA^+^-M2BP diagnostic performance in determination of liver fibrosis stage ≥F3.

                                      Cut-off value   AUC     95% CI         Sensitivity   Specificity   P value    Difference between areas (Mac 2 *vs.* ARFI median)   P value
  --------------------- ------------- --------------- ------- -------------- ------------- ------------- ---------- ---------------------------------------------------- ---------
  **Total; N=70**                                                                                                                                                        
  F0--F2 *vs.* F3--F4   Mac 2         1.32            0.712   0.591--0.814   72.2          61.76         0.0006     0.0792                                               0.2057
                        ARFI median   1.88            0.791   0.677--0.879   86.11         70.59         \<0.0001                                                        
  **HBV; n=33**                                                                                                                                                          
  F0--F2 *vs.* F3--F4   Mac 2         0.96            0.651   0.466--0.808   81.25         58.82         0.1404     0.165                                                0.0816
                        ARFI median   1.89            0.816   0.643--0.929   87.50         76.47         0.0001                                                          
  **HCV; n=27**                                                                                                                                                          
  F0--F2 *vs.* F3--F4   Mac 2         2.21            0.836   0.648--0.948   72.22         100.00        \<0.0001   0.142                                                0.1782
                        ARFI median   2.03            0.694   0.493--0.853   77.78         60.00         0.0697                                                          

AUC -- area under the ROC (receiver operating characteristic) curve; CI -- confidence interval. The AUC values were compared by DeLong's test.
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